Welcome to BioSeeker Group!

Hematological Cancers - A Therapeutic & Competitive Insight

Additional Information

Published Date Oct 16, 2006
Pages 197
PDF Fact Sheet View Fact Sheet for the report Hematological Cancers - A Therapeutic & Competitive Insight in PDF
Format PDF
Publisher BioSeeker Group

Availability: In stock

$2,950.00

Quick Overview

BioSeeker Group has studied the progress of 125 of the most prominent drugs in development for the treatment of hematological cancers. This extensive 190+ pages report not only describes and analyzes the latest years of progress in lymphoma and leukemia, it also provides an insight and framework to understand this complex field.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Hematological Cancers - A Therapeutic & Competitive Insight.

    To find out more about Hematological Cancers - A Therapeutic & Competitive Insight, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Hematological Cancers - A Therapeutic & Competitive Insight is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Introduction

Lymphoma is a broad term encompassing a variety of cancers of the lymphatic system. The two main groups of lymphoma in humans are Hodgkin’s disease (characterized by the growth of Reed-Sternberg cells) and the non-Hodgkin’s lymphoma. The world prevalence is approximately 650,000 cases, of which 300,000 are low grade and 350,000 are aggressive. The lymphoma market is a complex topic and several pitfalls await actors not well prepared. BioSeeker Group will guide through this field and bring structure and knowledge enables our customers to analyze opportunities. This report will help to answer questions on the subject of additional lymphoma treatments beyond Rituxan.
As well, leukemia includes a broad variety of histological separate disorders which make the leukemia market segmented. And even though a high level of unmet medical need, together with its dependence on chemotherapy, leukemia has not historically been the focus of significant R&D investment for emerging drugs in the pharmaceutical industry. This has now clearly changed with the launch of Novartis’ Gleevec (imatinib mesylate) for chronic myeloid leukemia, which is presenting the industry with proof that development within the leukemia market produces lucrative returns. Gleevec saw sales rise of 32 percent to $2.2 billion during 2005. Consequently, the historical general conception that relatively low prevalence diseases, has been insufficient in size to allow companies to quickly regain their investment is clearly out of date. In this perspective enhanced development is expected.

Research and analysis highlights

BioSeeker Group has studied the progress of 125 of the most prominent drugs in development for the treatment of hematological cancers. The most actively discussed and interesting drugs were selected and presented. A collection of emerging facts suggest that numerous of the new targeted therapies are agents that cannot just be added into treatment regimens with conventional drugs. A few of them might have isolated properties on certain biologic targets that may require to be modulated in particular ways before or after cytotoxic chemotherapy. Among the emerging therapeutic strategies, passive and active immunotherapies have clearly continued to be leading strategies. Small molecule apoptotic inducers and kinase inhibitors are as well in the forefront.
This extensive 190+ pages report not only describes and analyzes the latest years of progress in lymphoma and leukemia, it also provides an insight and framework to understand this complex field. In this report, BioSeeker provides one of the most comprehensive coverage of the R&D trends to set the future marketplace. We present both an overview and a detailed description on the progress of 100 key drugs in Phase II and III development, together with general descriptions on drugs and targets. Among these drugs BioSeeker clearly sees a substantial progress for some while others have failed. There will be a more intense competition in several of the sub-markets and current treatments will be changed for the benefit of more innovative therapies.

Scope of this report

  • Thorough examination of status and impact of several novel drugs in development
  • Discussion of the challenges in current and future treatment strategies
  • Anticancer pipeline of most companies in the field

Key reasons to read this report

  • Explore the strengths and weaknesses associated with compounds in clinical development. Scientific rationale for most novel therapeutics in R&D, and the results of clinical trials to date.
  • Gain insight into the current challenges and commercial opportunities associated with therapy for the hematological cancers.
  • More than 190 high quality references.

Some of the drugs included in this analysis

AG-858, Aldesleukin , Alemtuzumab, AP23573, Apolizumab, Arsenic trioxide, Atra, Avastin, BAY 43-9006, Bevacizumab, BiovaxID , Bortezomib , CEP-701, Ceplene, Clofarabine, Cloretazine, CMC-544 , Decitabine, Enzastaurin , Epratuzumab, FavId , FK228, Flavopiridol, Gemtuzumab, Genasense, Gvax, IDEC-114 , Imatinib, Marqibo, MyVax, Nelarabine , OSI-461, Pixantrone , PKC412, PTK787, Rituximab, SGN-30, SGN-40 , SU5416, Temsirolimus , Troxacitabine, Valspodar, VELCADE, Xcytrin, Zanolimumab, Zarnestra etc.

Some of the companies included in this analysis

Abgenix (Amgen), Accentia BioPharmaceuticals, Antigenics, Bayer, Bioenvision, Biogen Idec, BTG, Cell Genesys, Cell Therapeutics, Cephalon, Chiron (now Novartis) Corporation, Corixa (GSK), Cyclacel Group (Cyclacel), Eli Lilly, Exelixis, Favrille, Genentech, Genitope, Genmab, Genta, GlaxoSmithKline, Immunomedics, Inex Pharmaceuticals, Johnson & Johnson, Millennium Pharmaceuticals, Novartis, Pharmacyclics, Protein Design Labs, Roche, Sanofi-Aventis, Schering-Plough, Seattle Genetics, SuperGen, Vion Pharmaceuticals, Wyeth etc.

Companies Mentioned Include:

- Abgenix (Amgen)
- Accentia BioPharmaceuticals
- Antigenics
- Bayer
- Bioenvision
- Biogen Idec
- BTG
- Cell Genesys
- Cell Therapeutics
- Cephalon
- Chiron (now Novartis) Corporation
- Corixa (GSK)
- Cyclacel Group (Cyclacel)
- Eli Lilly
- Exelixis
- Favrille
- Genentech
- Genitope
- Genmab
- Genta
- GlaxoSmithKline
- Immunomedics
- Inex Pharmaceuticals
- Johnson & Johnson
- Millennium Pharmaceuticals
- Novartis
- Pharmacyclics
- Protein Design Labs
- Roche
- Sanofi-Aventis
- Schering-Plough
- Seattle Genetics
- SuperGen
- Vion Pharmaceuticals
- Wyeth
Some of the drugs included in this analysis:

- AG-858, Aldesleukin , Alemtuzumab, AP23573, Apolizumab, Arsenic trioxide, Atra, Avastin, BAY 43-9006, Bevacizumab, BiovaxID , Bortezomib , CEP-701, Ceplene, Clofarabine, Cloretazine, CMC-544 , Decitabine, Enzastaurin , Epratuzumab, FavId , FK228, Flavopiridol, Gemtuzumab, Genasense, Gvax, IDEC-114 , Imatinib, Marqibo, MyVax, Nelarabine , OSI-461, Pixantrone , PKC412, PTK787, Rituximab, SGN-30, SGN-40 , SU5416, Temsirolimus , Troxacitabine, Valspodar, VELCADE, Xcytrin, Zanolimumab, Zarnestra etc.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Hematological Cancers - A Therapeutic & Competitive Insight.
    To find out more about Hematological Cancers - A Therapeutic & Competitive Insight, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Hematological Cancers - A Therapeutic & Competitive Insight is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Oncology' category:


A Decision Support Tool for Optimizing the Melanoma Pipeline: From Research and Development to Market
This report comprises defined and up to date development strategies for 218 melanoma drugs within the portfolio of 138 companies, from Ceased to Marketed. The report extensively analyses their 170 identified drug targets, organized into 151 drug target strategies, and assesses them in eight different compound strategies in melanoma. Learn More


Triple Analysis: Colorectal Cancer, Leukemia and Angiogenesis
This triple analysis focuses on cancer drug development strategies in both Colorectal Cancer and Leukemia and by the mechanism/target/effect of Angiogenesis. Learn More